LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Efficacy of XELOX adjuvant chemotherapy for gastric mixed adenoneuroendocrine carcinoma

Photo by nci from unsplash

Abstract Rationale: Mixed adenoneuroendocrine carcinoma (MANEC) is a rare neoplasm, and consensus on the treatment is unavailable. Patient concern: A 60-year-old Chinese man presented with obstructive symptoms while eating and… Click to show full abstract

Abstract Rationale: Mixed adenoneuroendocrine carcinoma (MANEC) is a rare neoplasm, and consensus on the treatment is unavailable. Patient concern: A 60-year-old Chinese man presented with obstructive symptoms while eating and paroxysmal stomach pain for more than a month. Diagnosis: MANEC was diagnosed based on clinical manifestations, imaging findings, and pathological examinations. Interventions: The patient underwent radical gastrectomy and received XELOX adjuvant chemotherapy (oxaliplatin 200 mg day 1 + capecitabine 1.5 g twice a day) after surgery. Outcomes: After 4 cycles of XELOX adjuvant chemotherapy were administered, abdominal computerized tomography and liver magnetic resonance showed liver metastasis. Lessons: The therapy of gastric MANEC is based on surgical operation, and adjuvant chemotherapy program has an important influence on its prognosis. Therefore, further studying the effectiveness of XELOX adjuvant chemotherapy for gastric MANEC is necessary.

Keywords: chemotherapy; mixed adenoneuroendocrine; adjuvant chemotherapy; xelox adjuvant; adenoneuroendocrine carcinoma; chemotherapy gastric

Journal Title: Medicine
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.